Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2010

View Archived Issues

A potential covalent HIV vaccine neutralizes diverse HIV strains

LLS and Shape Pharma join to develop SHP-141 in cutaneous T-cell lymphoma

SLC22A4, SLC22A5 and KIF3A SNPs linked to tuberculosis in Thai population

Trimetazidine add-on regimen is safe and effective in acute myocardial infarction

DiaMedica initiates autoimmune program with DM-99

Covidien acquires Somanetics

Isis Pharma achieves milestone in collaboration with GSK

Marina Biotech acquires Novosom's Smarticles delivery system

Pharmasset begins phase Ib PSI-938 trial in chronic hepatitis C

Addex Pharmaceuticals presents new mGlu4 receptor modulators

Bionovo moves Menerba to phase III testing in Europe

GlaxoSmithKline discloses novel CCR2 receptor antagonists

New antineoplastic agents identified by U.S. and Chinese scientists

Resverlogix claims new regulators of ApoA-I expression

Intercept and NIDDK join to develop obeticholic acid in NASH

New DPP-4 inhibitors described by Indian researchers

Optimer submits fidaxomicin MAA to EMA for CDI

HemaQuest raises extra funds to advance HQK-1001 and HQK-1004

Anthera begins phase IIb PEARL-SC trial of A-623 in SLE

Liposomal Grb-2 enters phase I trial in AML, CML, ALL and MDS

Daiichi Sankyo and Sanofi Pasteur end shareholder agreement for SPDS Vaccine

COMP recommends orphan drug status for XOMA-052 in Behcet's disease

GSK licenses new antibiotic for Gram-negative infections from Anacor

Methyl jasmonate is cytotoxic in cervical cancer cells irrespective of HPV status

Scientists identify DB-766 as new candidate therapeutic for Chagas' disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...